The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients
Abstract
OBJECTIVE: The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder. METHOD: Following a 1-week placebo lead-in, 177 adult outpatients with major depressive disorder were randomly assigned to receive transdermal selegiline (20 mg applied once daily by means of a 20-cm(2) patch) (N=89) or placebo (N=88) for 6 weeks. The patients followed a tyramine-restricted diet during the medication trial and for 2 weeks after completion of treatment. Response to medication or placebo was measured by using the 17-item and 28-item versions of the Hamilton Depression Rating Scale, the Montgomery-Asberg Depression Rating Scale, and the Clinical Global Impression (CGI) severity and improvement measures. RESULTS: Greater improvement was observed after 6 weeks in patients treated with transdermal selegiline than in those given placebo according to all measures. A statistically significant difference between drug and placebo was seen in Hamilton depression scale and Montgomery-Asberg Depression Rating Scale scores as early as week 1 of treatment. There were no differences in the adverse event profile of the patients given selegiline and those given placebo with the exception of application-site reactions, which were more common with the selegiline transdermal system. No orthostatic hypotensive or hypertensive reactions were observed. CONCLUSIONS: Transdermal selegiline (20 mg applied once daily by means of a 20-cm(2) patch) administered for 6 weeks was an effective and well-tolerated treatment for adult outpatients with major depression. The typical side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
MONOAMINE OXIDASE: From Genes to Behavior
Shih, J. C., Chen, K., & Ridd, M. J. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.197 · Cited by 1,206
Healy, D. (1998) · DigitalGeorgetown (Georgetown University Library) · Cited by 467
Tranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
Mann, J. J. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010047007 · Cited by 178
Deprenyl (selegiline): the history of its development and pharmacological action
Knoll, J. E. (1983) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1983.tb01517.x · Cited by 167
High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland, T., Cohen, R. M., Molchan, S. E., Lawlor, B. A., Mellow, A. M., Newhouse, P. A., Tariot, P. N., Mueller, E. A., & Murphy, D. L. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950080019003 · Cited by 118
Thompson, C. M., Peveler, R., Stephenson, D., & McKendrick, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.3.338 · Cited by 103
Tyramine pressor sensitivity changes during deprenyl treatment
Sunderland, T., Mueller, E. A., Cohen, R. M., Jimerson, D. C., Pickar, D., & Murphy, D. L. (1985) · Psychopharmacology · doi:10.1007/bf00427904 · Cited by 81
Predictors and Timing of Adverse Experiences During Transdermal Nicotine Therapy
Gourlay, S. G., Forbes, A. B., Marriner, T., & McNeil, J. J. (1999) · Drug Safety · doi:10.2165/00002018-199920060-00007 · Cited by 50
A placebo-controlled trial of L-deprenyl in atypical depression.
McGrath, P. J., Jw, S., Harrison, W. M., Wager, S., En, N., & Quitkin, F. M. (1989) · PubMed · Cited by 45
Mawhinney, M., Cole, D., & Azzaro, A. J. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2003.tb02430.x · Cited by 43
Efficacy of intravenous citalopram compared with oral citalopram for severe depression
Guelfi, J., Strub, N., & Loft, H. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00120-2 · Cited by 33
A Possible L-Deprenyl Induced Hypertensive Reaction
McGrath, P. J., Stewart, J. W., & Quitkin, F. M. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198908000-00024 · Cited by 27
Barrett, J. S., Hochadel, T. J., Morales, R. J., Rohatagi, S., DeWitt, K. E., Watson, S. K., Darnow, J., Azzaro, A. J., & DiSanto, A. R. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04786.x · Cited by 15
Selegiline and Other Atypical Monoamine Oxidase Inhibitors in Depression
Bodkin, J. A., & Kwon, A. (2001) · Psychiatric Annals · doi:10.3928/0048-5713-20010601-08 · Cited by 11
Self-citation
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Finberg, J. P. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.010 · Cited by 257
Shimazu, S., & Miklya, I. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.016 · Cited by 57
Metadata
- Authors
- Bodkin, J. A., & Amsterdam, J. D.
- Venue
- American Journal of Psychiatry
- Published
- 2002-11-01
- Volume
- 159
- Issue
- 11
- Pages
- 1869-1875
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2166919399
- Cited by
- 318
- References
- 16
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.